Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SpaceXs rally is drawing attention after Morgan Stanley reiterated a bullish view ahead of Starship Flight 15, with traders also pointing to breakout momentum and possible short-covering. Bulls are celebrating the move, while skeptics question the valuation and flag upcoming share unlocks.

Novavaxs sharp rally is being linked by traders to reports of a suspected plague exposure in Russia, which has revived pandemic-preparedness speculation around vaccine stocks. The community also points to Novavaxs partner vaccine business and heavy short interest, debating whether the move reflects fundamentals, outbreak-driven FOMO, or a potential short squeeze.

Shareholder approval of Evernorths merger with Armada cleared the way for Evernorth to trade as XRPN, with the company expected to hold a large XRP treasury at closing. Traders have fueled a sharp, volatile run on expectations around the Nasdaq debut and XRP exposure, while others warn that the common shares low-float premium may fade as warrants become exercisable and the valuation is debated against the underlying assets.

Amazons reported plan to move Nvidia AI chips into an investor-backed vehicle and lease them back has prompted debate over whether it is balance-sheet management or a warning sign about AI spending. That discussion sits alongside widespread frustration with AMZNs choppy underperformance, while bulls point to AWS and AI demand as reasons for optimism.

GRRR is under pressure as traders focus on uncertainty around financing its AI data-center projects, with fears of further dilution and doubts that announced contracts will translate into revenue and cash flow. Bulls point to Yotta deployment progress and the companys contract backlog, but many are waiting for clearer financing details and proof of execution.

Capricors 24-month HOPE-3 open-label extension data on deramiocels effect on upper-limb decline in Duchenne muscular dystrophy has renewed attention ahead of the FDA decision. Despite optimism about the data, the share-price drop has fueled debate over whether it can overcome prior statistical concerns, with some traders highlighting an analysts expectation of a complete response letter and others viewing the data as supportive of approval.

AAOI is drawing attention as traders react to the reported completion of its at-the-market share-sale program, which they hope will ease dilution and selling pressure. Bulls also point to AI data-center optics demand, while skeptics remain concerned about further dilution and the stocks volatility.

Vaxcytes VAX-31 met the primary endpoints in its pivotal Phase 3 OPUS-1 trial in adults, fueling a sharp rally and optimism about its potential to compete with established pneumococcal vaccines. Traders are also debating dilution risk from the proposed stock and convertible-note offerings, alongside profit-taking and short-term volatility.

Redwires follow-on contract to supply two ROSA solar-array wings for Axiom Stations second module is drawing attention, extending its existing work on the station. Traders are frustrated that the shares have fallen despite the positive contract news, with some calling it a sell-the-news move and others pointing to possible ATM-related dilution as a source of pressure.

Jobys steep share-price decline has intensified concerns about cash burn, potential dilution, insider selling and the time required to secure FAA certification and reach profitability. Bulls cite Texas eIPP flights, an autonomous cross-country demonstration and certification progress as commercialization milestones, while skeptics argue they do not resolve the funding and timeline risks.